肾细胞癌生物学的新见解。
New insights into the biology of renal cell carcinoma.
机构信息
Howard Hughes Medical Institute, 4000 Jones Bridge Road, Chevy Chase, MD 20815, USA.
出版信息
Hematol Oncol Clin North Am. 2011 Aug;25(4):667-86. doi: 10.1016/j.hoc.2011.04.004.
Abstract
Ninety percent or more of kidney cancers are believed to be of epithelial cell origin, and are referred to as renal cell carcinoma (RCC), which are further subdivided based on histology into clear-cell RCC (75%), papillary RCC (15%), chromophobe tumor (5%), and oncocytoma (5%). Some genes confer an increased risk of these various histologic RCC subtypes. In practice, there is some overlap among the histologic subtypes, and there are some shared molecular features among these tumor types. This review focuses primarily on the most common form of RCC, clear-cell renal carcinoma, noting some recent advances in the other histologic subtypes.
摘要
据信，超过 90%的肾癌来源于上皮细胞，被称为肾细胞癌（RCC），根据组织学进一步细分为透明细胞 RCC（75%）、乳头状 RCC（15%）、嫌色细胞肿瘤（5%）和嗜酸细胞瘤（5%）。一些基因会增加这些不同组织学 RCC 亚型的风险。实际上，组织学亚型之间存在一些重叠，这些肿瘤类型之间也存在一些共同的分子特征。本综述主要关注最常见的 RCC 形式，即透明细胞肾细胞癌，并注意到其他组织学亚型的一些最新进展。
相似文献
1
New insights into the biology of renal cell carcinoma.肾细胞癌生物学的新见解。
Hematol Oncol Clin North Am. 2011 Aug;25(4):667-86. doi: 10.1016/j.hoc.2011.04.004.
2
Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma.四个基因之间的信使核糖核酸表达比率可预测肾细胞癌的亚型，并区分嗜酸细胞瘤与癌。
Clin Cancer Res. 2005 Sep 15;11(18):6558-66. doi: 10.1158/1078-0432.CCR-05-0647.
3
Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.von Hippel-Lindau 基因突变可增加透明细胞肾细胞癌自然杀伤细胞的易感性。
Oncogene. 2011 Jun 9;30(23):2622-32. doi: 10.1038/onc.2010.638. Epub 2011 Jan 24.
4
Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases.肾脏散发性嗜酸细胞瘤/嫌色细胞混合瘤：14 例临床病理、组织形态学、免疫组织化学、超微结构和分子细胞遗传学研究。
Virchows Arch. 2010 Apr;456(4):355-65. doi: 10.1007/s00428-010-0898-4. Epub 2010 Mar 19.
5
Imprint cytologic features of chromophobe renal cell carcinoma morphologically resembling renal oncocytoma: is this an oncocytic variant of chromophobe renal cell carcinoma?具有类似肾嗜酸细胞瘤形态学特征的嫌色性肾细胞癌的印片细胞学特征：这是嫌色性肾细胞癌的嗜酸细胞变体吗？
Diagn Cytopathol. 2010 Jul;38(7):509-13. doi: 10.1002/dc.21256.
6
Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes.KAI1转移抑制蛋白在肾细胞肿瘤组织学亚型中的差异表达。
J Urol. 2009 May;181(5):2305-11. doi: 10.1016/j.juro.2009.01.003. Epub 2009 Mar 19.
7
Loss of Von Hippel-Lindau () Tumor Suppressor Gene Function: -HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC).抑癌基因 VHL 失活：HIF 通路与转移性肾细胞癌（RCC）治疗新进展。
Int J Mol Sci. 2021 Sep 10;22(18):9795. doi: 10.3390/ijms22189795.
8
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.缺氧、缺氧诱导转录因子与肾癌
Eur Urol. 2016 Apr;69(4):646-657. doi: 10.1016/j.eururo.2015.08.007. Epub 2015 Aug 19.
9
Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes.基因表达谱分析可将嫌色性肾细胞癌与嗜酸细胞瘤区分开来，并鉴定出囊泡运输蛋白和细胞连接蛋白为差异表达基因。
Clin Cancer Res. 2006 Dec 1;12(23):6937-45. doi: 10.1158/1078-0432.CCR-06-1268.
10
Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.在透明细胞肾细胞癌中，Rho相关激酶1抑制与VHL（希佩尔-林道）缺陷具有合成致死性。
Oncogene. 2017 Feb 23;36(8):1080-1089. doi: 10.1038/onc.2016.272. Epub 2016 Nov 14.
引用本文的文献
1
Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis.替沃扎尼单药一线治疗转移性肾细胞癌且预后良好的患者
Curr Oncol Rep. 2024 Dec;26(12):1639-1650. doi: 10.1007/s11912-024-01613-7. Epub 2024 Nov 20.
2
Radiogenomics and Texture Analysis to Detect von Hippel-Lindau (VHL) Mutation in Clear Cell Renal Cell Carcinoma.利用放射基因组学和纹理分析检测透明细胞肾细胞癌中的冯·希佩尔-林道（VHL）突变
Curr Issues Mol Biol. 2024 Apr 8;46(4):3236-3250. doi: 10.3390/cimb46040203.
3
Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?抗血管生成药物与检查点抑制剂联合治疗肾细胞癌：整体是否大于部分之和？
Cancers (Basel). 2022 Jan 27;14(3):644. doi: 10.3390/cancers14030644.
4
Lipid metabolism reprogramming in renal cell carcinoma.肾细胞癌中的脂质代谢重编程。
Cancer Metastasis Rev. 2022 Mar;41(1):17-31. doi: 10.1007/s10555-021-09996-w. Epub 2021 Nov 6.
5
What morphology can teach us about renal cell carcinoma clonal evolution.形态学能让我们了解到关于肾细胞癌克隆进化的哪些信息。
Kidney Cancer J. 2020 Sep;18(3):68-76.
6
Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response.单细胞分析肾细胞癌揭示肿瘤微环境、细胞起源和治疗反应的见解。
Proc Natl Acad Sci U S A. 2021 Jun 15;118(24). doi: 10.1073/pnas.2103240118.
7
Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma.当前肾细胞癌免疫逃逸机制的研究进展及新兴免疫治疗策略
Front Immunol. 2021 Mar 9;12:639636. doi: 10.3389/fimmu.2021.639636. eCollection 2021.
8
The mA RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor.mA RNA 去甲基酶 FTO 是一种与 VHL 肿瘤抑制因子相互作用的缺氧诱导因子非依赖性合成致死伴侣。
Proc Natl Acad Sci U S A. 2020 Sep 1;117(35):21441-21449. doi: 10.1073/pnas.2000516117. Epub 2020 Aug 19.
9
The immunology of renal cell carcinoma.肾细胞癌的免疫学。
Nat Rev Nephrol. 2020 Dec;16(12):721-735. doi: 10.1038/s41581-020-0316-3. Epub 2020 Jul 30.
10
Leveraging insights into cancer metabolism-a symposium report.利用癌症代谢研究的新见解——研讨会报告
Ann N Y Acad Sci. 2020 Feb;1462(1):5-13. doi: 10.1111/nyas.14274. Epub 2019 Dec 2.
本文引用的文献
1
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.外显子组测序鉴定出肾癌中 SWI/SNF 复合物基因 PBRM1 的高频突变。
Nature. 2011 Jan 27;469(7331):539-42. doi: 10.1038/nature09639. Epub 2011 Jan 19.
2
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3.全基因组关联研究鉴定出肾细胞癌的两个易感性位点，位于 2p21 和 11q13.3。
Nat Genet. 2011 Jan;43(1):60-5. doi: 10.1038/ng.723. Epub 2010 Dec 5.
3
VHL inactivation induces HEF1 and Aurora kinase A.VHL 失活可诱导 HEF1 和 Aurora 激酶 A。
J Am Soc Nephrol. 2010 Dec;21(12):2041-6. doi: 10.1681/ASN.2010040345. Epub 2010 Sep 23.
4
Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability.定量图像分析鉴定 pVHL 为微管动态不稳定性的关键调节因子。
J Cell Biol. 2010 Sep 20;190(6):991-1003. doi: 10.1083/jcb.201006059.
5
O2 regulates stem cells through Wnt/β-catenin signalling.O2 通过 Wnt/β-catenin 信号调节干细胞。
Nat Cell Biol. 2010 Oct;12(10):1007-13. doi: 10.1038/ncb2102. Epub 2010 Sep 19.
6
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer.沙利度胺（CNTO 328），一种抗白细胞介素-6 单克隆抗体，治疗转移性肾细胞癌的 I/II 期研究。
Br J Cancer. 2010 Oct 12;103(8):1154-62. doi: 10.1038/sj.bjc.6605872. Epub 2010 Aug 31.
7
Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy.心肌细胞中缺氧诱导因子脯氨酰羟化酶活性的丧失可模拟缺血性心肌病。
Circulation. 2010 Sep 7;122(10):1004-16. doi: 10.1161/CIRCULATIONAHA.109.922427. Epub 2010 Aug 23.
8
The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth.组蛋白去甲基化酶 JMJD2B 受雌激素受体 α 和缺氧的调节，是雌激素诱导生长的关键介质。
Cancer Res. 2010 Aug 15;70(16):6456-66. doi: 10.1158/0008-5472.CAN-10-0413. Epub 2010 Aug 3.
9
Effects of HIF-1alpha and HIF2alpha on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts.缺氧诱导因子-1alpha 和缺氧诱导因子-2alpha 对透明细胞肾细胞癌 786-0 异种移植瘤生长和代谢的影响。
J Oncol. 2010;2010:757908. doi: 10.1155/2010/757908. Epub 2010 Jun 27.
10
Targeting the ANGPT-TIE2 pathway in malignancy.针对恶性肿瘤中的 ANGPT-TIE2 通路。
Nat Rev Cancer. 2010 Aug;10(8):575-85. doi: 10.1038/nrc2894.
Zotero 插件